The steps vendors can take to mitigate racial bias in digital health tools

Marten den Haring, CEO of Lirio, says the company uses its Large Behavior Model, which blends behavioral science with artificial intelligence, with the goal of driving consumer engagement in healthcare at the personal level.

Mati Gill, AION Labs CEO, provides an update on the company’s nine AI-enabled drug discovery portfolio companies, how the organizations are making an impact in life sciences and what’s next for AION, including exploring quantum technologies.

The U.S. Food and Drug Administration's validation requirements process for drug development is a good model for healthcare artificial intelligence governance, explains Michael Abrams, managing partner at Numerof & Associates.